{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:39:22Z","timestamp":1792823962963,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020425","name":"Lyda Hill Philanthropies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.canlet.2026.218855","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:31:38Z","timestamp":1790404298000},"page":"218855","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CD70-driven immunosuppression in mantle cell lymphoma identifies a vulnerability to CD70-Directed bispecific antibody modalities"],"prefix":"10.1016","volume":"661","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8439-6043","authenticated-orcid":false,"given":"Yixin","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6231-5225","authenticated-orcid":false,"given":"Fangfang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6618-3768","authenticated-orcid":false,"given":"Yijing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng-Huan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.canlet.2026.218855_bib1","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3109\/10428194.2013.876634","article-title":"Recent advances in mantle cell lymphoma: report of the 2013 mantle cell lymphoma consortium workshop","volume":"55","author":"Gordon","year":"2014","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.canlet.2026.218855_bib2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1053\/j.semdp.2011.02.010","article-title":"Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markers","volume":"28","author":"Sander","year":"2011","journal-title":"Semin. Diagn. Pathol."},{"issue":"14","key":"10.1016\/j.canlet.2026.218855_bib3","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1182\/bloodadvances.2022007247","article-title":"Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma","volume":"6","author":"Narkhede","year":"2022","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.canlet.2026.218855_bib4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2023021306","article-title":"CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study","volume":"143","author":"Minson","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.canlet.2026.218855_bib5","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.canlet.2026.218855_bib6","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.canlet.2026.218855_bib7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218855_bib8","article-title":"Three-year Follow-Up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","author":"Wang","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.canlet.2026.218855_bib9","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1182\/blood.2020010527","article-title":"SOX11, CD70, and treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma","volume":"138","author":"Balsas","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.canlet.2026.218855_bib10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/hematology.2019000011","article-title":"Molecular profiling and management of mantle cell lymphoma","volume":"2019","author":"Ruan","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1016\/j.canlet.2026.218855_bib11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10637-018-0655-0","article-title":"A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma","volume":"37","author":"Phillips","year":"2019","journal-title":"Invest New Drugs"},{"issue":"1","key":"10.1016\/j.canlet.2026.218855_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12943-022-01655-0","article-title":"TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma","volume":"21","author":"Jiang","year":"2022","journal-title":"Mol. Cancer"},{"issue":"14","key":"10.1016\/j.canlet.2026.218855_bib13","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1158\/0008-5472.CAN-11-2791","article-title":"CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth","volume":"72","author":"Claus","year":"2012","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218855_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: the new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218855_bib15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s10142-023-00977-6","article-title":"Comprehensive analysis of prognosis and immune function of CD70-CD27 signaling axis in pan-cancer","volume":"23","author":"Kong","year":"2023","journal-title":"Funct. Integr. Genomics"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:19:34Z","timestamp":1792822774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526006191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":15,"alternative-id":["S0304383526006191"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218855","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD70-driven immunosuppression in mantle cell lymphoma identifies a vulnerability to CD70-Directed bispecific antibody modalities","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218855","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218855"}}